Gufic BioSciences' Q3 FY 2025-26 Quarterly Results
- 15 Feb 2026
Result Summary
- Gufic BioSciences Ltd reported a 2.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 10.8%.
- Its expenses for the quarter were down by 1.0% QoQ and up 16.9% YoY.
- The net profit decreased 26.2% QoQ and decreased 35.7% YoY.
- The earnings per share (EPS) of Gufic BioSciences Ltd stood at 1.24 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 232.20 | 239.17 | 209.66 | -2.9% | 10.8% |
Total Expenses | 214.48 | 216.56 | 183.40 | -1.0% | 16.9% |
Profit Before Tax | 17.72 | 22.60 | 26.26 | -21.6% | -32.5% |
Tax | 5.30 | 5.78 | 6.96 | -8.3% | -23.9% |
Profit After Tax | 12.42 | 16.82 | 19.31 | -26.2% | -35.7% |
Earnings Per Share | 1.24 | 1.68 | 1.93 | -26.2% | -35.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Gufic BioSciences Ltd is a pharmaceutical company headquartered in India, specializing in the development, manufacturing, and marketing of pharmaceutical products, including innovative healthcare solutions. The company has a diverse portfolio that includes Active Pharmaceutical Ingredients (APIs), finished formulations, and herbal formulations, primarily serving the healthcare and pharmaceuticals industry. Although specific recent developments are not provided here, companies in this sector typically focus on expanding their product lines, enhancing production capacities, and entering new markets to drive growth. Gufic BioSciences Ltd is known for its commitment to quality and innovation in its offerings, catering to both domestic and international markets.
Revenue
In Q3FY26, Gufic BioSciences Ltd reported a total income of ₹232.20 crores, reflecting a quarter-over-quarter (QoQ) decrease of 2.9% from ₹239.17 crores in Q2FY26. When compared to the same quarter in the previous year (Q3FY25), the total income increased by 10.8% from ₹209.66 crores. The year-over-year (YoY) growth indicates an upward trend in revenue generation, despite the slight dip observed on a sequential quarter basis. This fluctuation could be attributed to seasonal variations or market conditions affecting the pharmaceutical industry.
Profitability
The company's profitability metrics for Q3FY26 indicate a decline in profit figures. Profit Before Tax (PBT) stood at ₹17.72 crores, registering a significant QoQ decrease of 21.6% from ₹22.60 crores in Q2FY26, and a YoY decrease of 32.5% from ₹26.26 crores in Q3FY25. The Profit After Tax (PAT) was ₹12.42 crores, representing a 26.2% decrease QoQ from ₹16.82 crores and a 35.7% decrease YoY from ₹19.31 crores. Earnings Per Share (EPS) were ₹1.24, reflecting similar percentage declines as PAT in both QoQ and YoY comparisons. These declines highlight a contraction in profitability for the quarter under review.
Operating Metrics
Total expenses for Gufic BioSciences Ltd in Q3FY26 were ₹214.48 crores, showing a marginal decrease of 1.0% QoQ from ₹216.56 crores in Q2FY26. However, on a YoY basis, total expenses increased by 16.9% from ₹183.40 crores in Q3FY25. The tax expense for the quarter was ₹5.30 crores, down 8.3% QoQ from ₹5.78 crores and down 23.9% YoY from ₹6.96 crores. These metrics suggest adjustments in operational strategies or cost management practices impacting the expenditure and tax liabilities. Overall, these operating metrics provide insights into the company's operational efficiency and cost control during the period.